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Abstract
Background: Pre-eclampsia is a complication of pregnancy associated with activation of coagulation. It is caused by the
placenta, which sheds increased amounts of syncytiotrophoblast microvesicles (STBM) into the maternal circulation. We
hypothesized that STBM could contribute to the haemostatic activation observed in pre-eclampsia.
Methodology/Principal Findings: STBM were collected by perfusion of the maternal side of placentae from healthy
pregnant women and women with pre-eclampsia at caesarean section. Calibrated automated thrombography was used to
assess thrombin generation triggered by STBM-borne tissue factor in platelet poor plasma (PPP). No thrombin was detected
in PPP alone but the addition of STBM initiated thrombin generation in 14/16 cases. Pre-eclampsia STBM significantly
shortened the lag time (LagT, P = 0.01) and time to peak thrombin generation (TTP, P = 0.005) when compared to normal
STBM. Blockade of tissue factor eliminated thrombin generation, while inhibition of tissue factor pathway inhibitor
significantly shortened LagT (p = 0.01) and TTP (P,0.0001), with a concomitant increase in endogenous thrombin potential.
Conclusions/Significance: STBM triggered thrombin generation in normal plasma in a tissue factor dependent manner,
indicating that TF activity is expressed by STBM. This is more pronounced in STBM shed from pre-eclampsia placentae. As
more STBM are shed in pre-eclampsia these observations give insight into the disordered haemostasis observed in this
condition.
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Introduction
Pre-eclampsia is a relatively common pregnancy-specific
disorder affecting around 3% of pregnancies and is a major cause
of fetal and maternal mortality and morbidity worldwide. It is
characterized by hypertension, proteinuria, endothelial dysfunc-
tion and systemic activation of an inflammatory response [1].
During normal pregnancy, the placental syncytiotrophoblast
releases microvesicles (STBM) and soluble inflammatory media-
tors in [2] to the maternal circulation [2], leading to a low-level
physiological inflammatory response. In pre-eclampsia, there is
increased release of STBM and other inflammatory factors that
are thought to trigger the increased maternal inflammatory
response characteristic of the disease [3]. Normal pregnancy is
associated with a physiological increase in many procoagulant
factors and inhibitors of fibrinolysis, such that fibrinolytic activity is
reduced during pregnancy. In normal pregnancy, markers of in
vivo thrombin generation (thrombin-antithrombin complexes
[TAT], prothrombin fragment 1.2 [PF1.2] and D-dimer) are
slightly increased as is the endogenous thrombin potential (ETP)
[4].
The association between coagulation activation and pre-
eclampsia has long been recognized and includes excessive platelet
activation, increased fibrin degradation products and intervillous
fibrin deposition in the placenta [5]. The shift in the haemostatic
balance observed in normal pregnancy is exaggerated in pre-
eclampsia. In practice, a spectrum of haemostatic changes are
observed; from the subtle variation seen in in mild preeclampsia to
disseminated intravascular coagulation. Tissue factor is a member
of the cytokine receptor superfamily which is constitutively
expressed by most non-vascular and perivascular cells and initiates
the coagulation cascade following vascular injury [6]. It is essential
for the development of embryonic blood vessels, migration and
proliferation of vascular smooth muscle, and regulation of
inflammation [7,8]. The main physiological inhibitor of tissue
factor in blood is tissue factor pathway inhibitor (TFPI), whereas
tissue factor pathway inhibitor-2 (TFPI-2) is thought to be the
main inhibitor of coagulation on the placental surface [9],
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although TFPI-2 acts primarily on factor Xa rather than tissue
factor. It is thought that under normal circumstances cells in
contact with blood do not express physiologically active TF [10].
The amount of tissue factor in the blood of normal individuals is
controversial. Although circulating tissue factor has been reported
in normal individuals at concentrations as high as 37pM [11], the
consensus is that the level of circulating tissue factor in normal
individuals is extremely low [12,13], probably less than 20fM [14].
This is consistent with observations that sub-picomolar concen-
trations of tissue factor clot blood within a few minutes [10] and
that tissue factor expressing pericardial microvesicles, but not
normal plasma microvesicles, are thrombogenic in vivo [15]. Tissue
factor bearing microvesicles are increased in several pathological
states associated with thrombotic complications, e.g. sepsis, cancer
and cardiovascular disease [16].
The presence of active tissue factor on the placental syncytio-
trophoblast, which is in direct contact with the blood, is equally
controversial. Although it has been reported to be present on
membranes prepared by sonication of placental villi [17],
choriocarcinoma cell lines [17,18] and syncytiotrophoblasts
differentiated in vitro from primary villous trophoblasts [19],
histological studies have shown that it is present at high
concentration in the decidua but absent from syncytiotrophoblasts
[20–22]. However, more recently two groups [23,24] have
reported increased levels of tissue factor antigen and mRNA in
the syncytiotrophoblast of placentae from women with pre-
eclampsia.
The reasons for these conflicting reports may be the lack of
standardization of methods for the measurement of tissue factor
and poor specificity of the antibodies used [13]. It is now generally
agreed that the measurement of tissue factor activity is more
sensitive and specific than measurement of tissue factor antigen
[10,25]. Against this background, we studied the potential
thrombogenicity of STBM shed from the maternal surface of the
placenta as a model for the procoagulant state in pre-eclampsia.
Results
There was no significant difference in maternal age, parity or
body mass index between the normal and pre-eclamptic
pregnancies at the time of booking. As would be expected, birth
weight centile, gestational age and placental weight were all lower
in pre-eclamptic pregnancies. The maternal platelet count fell an
average of 736109/L in pre-eclamptic pregnancies but remained
close to baseline, or above, in all except one normal pregnancy
(Table 1).
Platelet poor plasma (PPP) alone generated no thrombin upon
recalcification. Endogenous thrombin potential (ETP) and peak
thrombin formation were significantly increased by the addition of
pre-eclampsia STBM compared to normal STBM, with concom-
itant reductions in median LagT and TTP (3.8 [IQR 2.4–6.8] v
8.3 [IQR 7.3–45.0] and 7.3 [IQR 4.6–12.4] v 15.8 [IQR 14.3–
55.4] minutes respectively) (Fig. 1A). STBM from three of the
normal pregnancy placentas generated little or no thrombin. By
contrast, all pre-eclampsia STBM produced at least 300 nM of
thrombin and reduced the LagT to less than 10 minutes.
Preincubation with an inhibitory anti-tissue factor antibody
eliminated all thrombin generation.
Blockade of TFPI resulted in all STBM preparations triggering
a minimum ETP value of 680 nM when added to PPP, but was
not sufficient to produce thrombin generation in PPP alone
(Fig. 1B). Shorter LagT and TTP were observed with pre-
eclampsia STBM than normal STBM. Preincubation with anti-
TFPI-2 has no statistically significant effect of thrombin genera-
tion, although there was a trend towards increased ETP and peak
(Fig. 1C).
The addition of recombinant tissue factor to PPP produced a
dose response reduction in LagT (Fig. 2). These data indicate that
the amount of active tissue factor present is approximately 0–100
pM/gram of protein on normal STBM and 40–800 pM/gram of
protein for pre-eclampsia STBM (Table 2).
Table 1. Patient characteristics.
Patient Maternal age BMI Parity Gestation (days) Birth weight centile Placental weight (g) Platelet count610
9/L
Booking Pre-delivery
N1 28 42.5 1 273 37.3 NA 208 183
N2 29 24.4 1 273 25.7 NA 269 312
N3 26 17.6 1 272 20.4 563 208 169
N4 36 24.1 1 274 79.7 NA 221 243
N5 38 25.0 1 290 77.6 772 212 210
N6 33 NA 1 267 78.3 929 198 242
N7 34 21.5 0 294 49.6 613 210 135
N8 33 31.0 1 268 62 638 213 176
PE1 24 30.8 1 255 0.4 524 261 252
PE2 39 26.4 1 246 10.8 579 307 179
PE3 44 25.5 1 274 51.6 700 273 281
PE4 41 39.1 2 210 0.8 284 248 112
PE5 31 26.7 2 231 0.6 646 284 168
PE6 42 22.3 1 248 8.1 458 299 256
PE7 29 22.6 1 271 22.6 617 278 132
PE8 31 23.8 0 234 12.2 315 233 222
doi:10.1371/journal.pone.0026313.t001
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It was notable that the only normal STBM sample (N7)
estimated to contain in excess of 60 pM/gram of active tissue
factor was from a patient whose platelet count had dropped by
756109/mL in the three weeks prior to delivery. Furthermore,
two of the three pre-eclampsia STBM samples (PE1 and PE3) with
less than 60 pM of tissue factor per gram of protein were obtained
from patients with late onset pre-eclampsia who were not receiving
anti-hypertensive therapy prior to delivery and whose platelet
count remained stable throughout pregnancy.
Discussion
Under normal circumstances, tissue factor is not expressed on
endothelial cells and other cells in direct contact with the blood.
Consequently, the presence, or otherwise, of tissue factor on the
syncytiotrophoblast with the potential to initiate coagulation, in
direct contact with maternal blood, has been controversial subject
for many years. This controversy arises in part from poor
methodological standardization which has led to conflicting
reports. Although tissue factor antigen has been reported on the
syncytiotrophoblast [17–24], the immunological methods used
may also detect inactivated forms and alternatively spliced forms
of the molecule which have no procoagulant activity [13].
We hypothesized that STBM shed during pre-eclamptic
pregnancies into the maternal circulation contain increased levels
of active tissue factor and that this could activate the coagulation
system. Our study is unique in two respects: firstly, tissue factor
activity rather than antigen was measured; and, secondly, this is
the first time that tissue factor has been demonstrated on STBM
rather than on the placental surface.
Our data confirm that negligible levels of active tissue factor
exist in normal plasma, and that subpicomolar amounts of tissue
factor can trigger coagulation [12–14]. The absence of thrombin
generation in PPP demonstrates that contact factor inhibition by
CTI in these experiments was complete. The absence of contact
activation, the complete inhibition of thrombin generation by
inhibitory tissue factor antibodies and the augmentation of
thrombin generation by TFPI blockade demonstrate that the
initiation of thrombin generation in these experiments was tissue
factor specific.
STBM shed from the maternal surface of the placenta express
significantly more active tissue factor in pre-eclampsia, as
demonstrated by an increase in both the amount and rate of
thrombin generation, with significantly shorter LagT and TTP
compared to normals. Elimination of TFPI activity with inhibitory
antibodies enhanced the sensitivity of the method, thus enabling
the detection of active tissue factor in all STBM preparations. In
contrast, blockade of TFPI-2 had minimal effect. This is consistent
with the expression of low levels of tissue factor by syncytiotro-
phoblast in normal pregnancy. The increased levels of active tissue
factor activity on STBM from pre-eclamptic pregnancies supports
previous reports of upregulation of tissue factor on the syncytio-
trophoblast during pre-eclampsia [23,24]. However, in contrast to
previous reports, we have demonstrated that this tissue factor is
present in an active form capable of initiating coagulation in
blood. Not only is there greater expression of tissue factor on pre-
eclampsia STBM but significantly more are shed into the maternal
circulation in pre-eclampsia, with estimates ranging from a 2–10
fold increase [26–30], which is consistent with reports of increased
numbers of circulating STBM in the blood of women with pre-
eclampsia [26,31,32] Together, these changes would be expected
to comprise a substantial intravascular pro-thrombotic stimulus.
Figure 1. The effect of STBM on thrombin generation parameters of normal platelet poor plasma. (A) STBM were added to platelet poor
plasma at a concentration 50 mg/mL. Following the addition of 4 mM phospholipid and 16 nM CaCl2, thrombin generation was monitored
continuously. Endogenous thrombin potential (ETP), time to start of thrombin generation, peak thrombin generation and time to peak thrombin
generation are shown for normal STBM and pre-eclampsia STBM (PET). (B) This was repeated after prior incubation with 25 mg/mL anti-TFPI and (C)
50 mg/mL anti-TFPI-2.
doi:10.1371/journal.pone.0026313.g001
Figure 2. The effect of recombinant tissue factor on thrombin
generation lag-time. Recombinant tissue factor was added to
platelet poor plasma (final concentration 0.3–12pM). Following the
addition of 4 mM phospholipid and 16 nM CaCl2, the mean lag time to
start of thrombin generation was recorded. Error bars represent the
standard deviation.
doi:10.1371/journal.pone.0026313.g002
Table 2. Tissue factor content of syncytiotrophoblast
microvesicles.
Sample Lag time (s) Tissue factor concentration (pg/g of protein)
N1 60.0 0
N2 7.8 51
N3 60.0 0
N4 40.7 7
N5 6.8 58
N6 7.5 54
N7 3.9 111
N8 8.7 47
PE1 9.7 43
PE2 4.0 106
PE3 6.3 63
PE4 3.6 123
PE5 8.5 48
PE6 2.6 225
PE7 1.6 812
PE8 2.0 401
N= normal STBM, PE + pre-eclampsia STBM.
doi:10.1371/journal.pone.0026313.t002
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Two of the lowest pre-eclampsia STBM tissue factor activity
levels were observed in women with mild late onset pre-eclampsia,
who maintained a steady platelet count throughout pregnancy. By
contrast, the women with severe early onset pre-eclampsia had
high levels of STBM tissue factor activity. Of the eight STBM
preparations obtained from normal pregnant women, only one
had a significant elevation of tissue factor activity. This patient had
a falling platelet count prior to delivery, which could be indicative
of a developing procoagulant state . These data suggest that high
tissue factor activity may precede overt disease and may be
associated with more severe disease.
There have been many reports of increased circulating levels of
tissue factor in pre-eclamptic women [29,31,33–35] but these
measurements have all been made using immunological methods
or poorly standardized functional assays, resulting in values several
orders of magnitude higher than those obtained by specific
functional assays. As subpicomolar quantities of tissue factor are
now known to initiate clotting, it is highly unlikely that these
measurements were detecting active tissue factor.
Given that tissue factor expression is generally in the order of
pM, the small number of circulating STBM [26,31,36] and the
rapid clearance of circulating microvesicles [37] and trophoblast
debris [38], it is unlikely that tissue factor positive STBM persist in
the circulation in sufficient numbers, or with sufficient antigen
density, for accurate detection by flow cytometry. However, the
shedding of tissue factor-bearing STBM into the maternal
circulation would be expected to increase markers of in vivo
thrombin generation and this is indeed the case [39–44].
While tissue factor is essential for placental and embryonic
development, abberant expression is associated with poor
pregnancy outcomes in mice [45]. Tissue factor has inflammatory
functions, both dependent and independent of coagulation
activation through the activation of protease-activated receptors
(PARs) [7] on endothelial cells, platelets, neutrophils and
monocytes. It has been reported that PAR-1 expression is
increased on villous trophoblasts in pre-eclampsia [46] and that
thrombin increases the release of soluble fms-like tryrosine kinase
(sFLT-1), a potent anti-angiogenic factor and a key player in pre-
eclampsia [47] suggesting a role for tissue factor and thrombin in
the pathogenesis of pre-eclampsia.
This study had some limitations.
Placental tissue factor is heavily glycosylated and is reported to
be 5-fold more active than recombinant tissue factor [48].
Consequently, we may have overestimated STBM tissue factor
expression as our calibration curve was performed using
recombinant tissue factor.
It was not possible to perfuse all the placentae obtained due to
excessive placental infarction or mechanical damage. Furthermore
the lobules selected for perfusion were those which were not
obviously infarcted. Consequently the samples collected may have
been biased towards less severe forms of pre-eclampsia. Due to
logistical issues, only those cases delivered by elective caesarean
section could be included which would also have excluded
inclusion of fulminating disease with emergency delivery.
We cannot discount the possibility that tissue factor was
produced ex vivo during the perfusion. However, this would not
explain the difference in tissue factor activity between normal and
pre-eclampsia placentae.
Blood samples were not obtained from the women prior to
delivery, so it was not possible to relate STBM tissue factor levels
with in vivo markers of thrombin generation.
In conclusion, we have shown that the placenta releases tissue
factor bearing microvesicles from the maternal face of the placenta
and tissue factor activity is increased in STBM released during
pre-eclampsia. The low level shedding of active tissue factor into
the maternal circulation via STBM may be responsible for the
physiologically important procoagulant state in normal pregnancy.
It is probable that the increased rate of STBM shedding combined
with higher tissue factor expression may contribute to ma-
ternal inflammation and disordered hemostasis observed in pre-
eclampsia.
Materials and Methods
Patient details
Placentae were obtained at caesarean section, without labour,
from healthy pregnant women or women with pre-eclampsia.
Women with pre-existing renal disease, previous surgery, insulin-
dependent diabetes or asthma requiring steroidal treatment were
excluded. Pre-eclampsia was diagnosed by new hypertension after
the 20th week of pregnancy (diastolic blood pressure $90 mmHg
on at least two occasions) and new proteinuria (2+ protein on
dipstick testing on 2 occasions;$500 mg/24 hour; or$50 mg/ml
protein/creatinine ratio) in the absence of urinary tract infection.
Inclusion criteria for normal pregnancy were: singleton pregnancy,
normal obstetric history; diastolic ,90 mmHg and systolic blood
pressure ,140 mmHg; and no significant proteinuria (,1+) and
congenitally normal livebirth at term. The study was approved by
the Mid and South Buckinghamshire Research Ethics Committee
and all participants gave written informed consent.
Reagents
Corn trypsin inhibitor (CTI) was purchased from Cambridge
Bioscience (Cambridge, UK). The antibodies used were: NDOG2
an in-house anti-syncytiotrophoblast antibody which recognizes
placental alkaline phosphatase [27]; polyclonal rabbit anti-human
tissue factor antibody, polyclonal rabbit anti-human TFPI
(American Diagnostica Inc. CT) and monoclonal anti-human
TFPI-2 (R&D Systems, Abingdon, UK). Fc receptor blocker was
obtained from Miltenyi Biotec, Bergisch Gladbach, Germany.
Thrombin generation was measured using MP Reagent (contain-
ing 4 mM phospholipid, final concentration), start reagent
(FluCaTM; containing 1/40 volume fluorogenic substrate,
16.7 nM calcium chloride, Hepes, pH 7.35) and Thrombin
Calibrator (all Diagnostica Stago, Asnie`res sur Seine, France).
Plasma preparation
The substrate plasma was prepared from blood collected from a
single normal fasting donor using a 19 G needle with minimal
suction and a light tourniquet into 0.106 mmol trisodium citrate
containing corn trypsin inhibitor (final concentration 20 mg/mL).
Platelet poor plasma (PPP) was prepared by double centrifugation
at 2500 g for 15 minutes with supernatant separation, and frozen
at 280uC until required.
Preparation of syncytiotrophoblast vesicles (STBM)
STBM were prepared using a dual placental perfusion system
[32]. Briefly, placentae obtained at caesarean section, without
labour were processed immediately. The whole placenta was laid
inside a Perspex water jacket maintained at 37uC. The fetal
circulation of a single lobule, not visibly infarcted, was perfused
with 0.1 mm filtered modified M-199 tissue culture medium,
containing 0.8% Dextran 20, 0.5% BSA, 5000 U/L sodium
heparin and 100,000 IU streptokinase at a rate of 5 mL/min. The
maternal side was perfused with modified M-199 tissue culture
medium containing 0.5% BSA and 5000 U/L sodium heparin at a
controlled rate of 20 ml/min and oxygenated with 95% O2,
5%CO2. To equilibrate the system, the lobule was initially
Tissue Factor in Pre-Eclampsia
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perfused for 20 min and the effluent of the maternal and fetal
circuits was discarded. After this time the maternal circuit was
closed containing 600 ml of fresh perfusion medium. The volume
of fetal effluent was measured every 2 min and the oxygen
concentration of the maternal side perfusate monitored continu-
ously to ensure stability. Pressure monitors were used on both the
maternal and fetal sides of the placenta to ensure no significant
deviations from baseline during the experimental period. After
3 hr, the maternal perfusate was centrifuged at 600 g for 10 min
to remove cellular debris. The remaining supernatant was
ultracentrifuged at 150,000 g to pellet the STBM. The resultant
pellets were pooled and washed in phosphate buffered saline (PBS)
and then resuspended in PBS to a final total protein concentration
(BCA protein assay kit) of 5 mg/ml and stored in aliquots at
280uC until use. Of the 10 normal and 10 pre-eclampsia
placentas collected for this study, it was not possible to perfuse
three pre-eclampsia placentas and two normal placentas due to
infarction or mechanical damage. The placental origin of the
STBM was verified by flow cytometry using NDOG2, a
trophoblast specific monoclonal antibody which recognises
placental alkaline phosphatase [49]. All STBM samples were
blocked with Fc receptor blocker for 10 min at 4uC before the
addition of NDOG2-FITC or IgG1 FITC isotype control. Flow
cytometry analysis was performed on a BD LSRII flow cytometer
(BD Biosciences), and data were analyzed by FACSDIVA
software. There was no significant difference in the percentage
of STBM which stained with the NDOG2 antibody between the
normal and pre-eclampsia STBM (median 91.7% v 85.3%;
P=NS).
Thrombin generation
Perfused STBM were diluted to 500 ng/mL and pre-incubated
with PBS, anti-TFPI, anti-TFPI-2 or anti-tissue factor. This
suspension was then added to PPP (final concentration; STBM
50 mg/mL; anti-TFPI 25 mg/mL; anti-TFPI-2 50 mg/mL and
anti-TF 20 mg/mL). Calibrated automated thrombin generation
was measured according to the method of Hemker et al. [50] with
the addition of 20 mg/mL CTI to prevent contact factor activation
[51]. Briefly, 80 mL of sample per well were added to a 96 well
plate followed by 20 mL of MP Reagent or 20 mL Thrombin
Calibrator. After incubation at 37uC for 20 minutes 20 mL start
reagent were added. Fluorescence intensity was measured
continuously for 60 minutes using a fluorescent plate reader
(Fluoroskan Ascent FL, Thermo Electron Corporation, Helsinki,
Finland) equipped with a 390/460 nm filter set. The fluorescent
signal was converted into thrombin concentration using the
internal thrombin calibrator and dedicated software (Thrombino-
scope bv, Maastricht, Netherlands). All samples with and without
calibrator were tested in duplicate wells. The endogenous
thrombin potential (ETP; i.e., the area under the curve) peak
thrombin generation (peak), lag time to start of thrombin
generation (LagT), time to peak thrombin generation (TTP), and
were recorded. If no thrombin generation was observed, the LagT
and TTP were recorded as 60 minutes. In CTI-treated plasma,
and in the presence of phospholipid, LagT is largely dependent on
tissue factor activity [12]. In order to estimate tissue factor
concentration, recombinant human tissue factor was added to
plasma (final dilutions of 0.3–12.0 pM) prior to measurement of
thrombin generation and tissue factor concentration was plotted
against LagT as previously described [12].
Statistics
Statistical analyses were performed using Graphpad Prism
software. Nonparametric statistics were used unless otherwise
stated. The statistical significance of differences between groups
was determined by the Mann Witney U test. P values ,0.05 were
considered significant.
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